Detalhe da pesquisa
1.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Lancet Oncol
; 18(4): 545-554, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28238593